

Original Research Article

Possible Impact of Select Trace Mineral Deficiency in HIV Seropositive Pregnant Women with/without Malaria co- infection in NAUTH, Nnewi, Nigeria

ABSTRACT

Aims: To evaluate the impact of HIV and malaria on serum Zinc (zn), Selenium (se) and Magnesium (mg) in HIV seropositive pregnant women in Nnewi, Nigeria.

Study design: This is a case-control study.

Place and Duration of Study: Prevention of Mother to Child transmission (PMTCT) of HIV Clinic of Nnamdi Azikiwe University Teaching Hospital, Nnewi, (NAUTH), Nigeria, between December, 2017 and April, 2018.

Methodology: We included 152 consented female participants (32 HIV seropositive pregnant women with malaria parasitaemia, 30 HIV seropositive pregnant women without malaria parasitaemia, 30 Malaria infected pregnant women, 30 pregnant women without HIV or malaria parasitaemia, 30 non-pregnant women without HIV or malaria infection; aged between 18 and 42 years). Screening for HIV antibodies and malaria parasite was double screened using National algorithm, rapid detection technique (RDT) and Giemsa staining microscopy technique respectively. Micronutrient levels were determined using atomic absorption spectrophotometry (AAS).

Results: When the mean zn, sel, and mg levels were compared between the test and control groups, significant decreases in serum zn (37.34 ± 6.7 , 36.70 ± 4.39), sel (29.93 ± 6.02 , 28.00 ± 5.04) and mg (2.41 ± 0.46 , 2.33 ± 0.14) were observed in HIV seropositive pregnant participants with/without malaria co-infection when compared with their corresponding controls Zn (45.1 ± 7.83 , 50.36 ± 8.73); Sel (31.46 ± 6.19 , 31.96 ± 6.81); Mg (2.62 ± 0.30) and ($P < .05$ respectively). BMI was significantly decreased while DBP and SBP were significantly increased in HIV seropositive pregnant women with malaria compared with their seronegative counterparts ($P < .05$ respectively)

Conclusion: The significant loss in BMI with derangement in serum zn, sel and mg levels in HIV seropositive pregnant women with/without malaria co-infection indicates high degree of malnutrition while the increased blood pressure suggests high blood pressure which might predispose the pregnant mothers to pre-eclampsia if not properly managed. Adequate micronutrient supplementation and effective anti malaria agent is strictly advocated in the routine management of HIV infected mothers during pregnancy to reduce the severity of the co-infection and adverse pregnancy complications especially in areas of malaria endemic transmissions.

Keywords: [HIV/malaria, co-infection, trace minerals, pregnancy]

18 **1. INTRODUCTION**

19

20 Human immune deficiency virus and malaria infection remain a major public health issue in
21 Nigeria health care system. Both infections pose great challenges in diagnosis and therapy
22 specifically during pregnancy with detrimental outcomes that may affect both the mother and
23 fetus [1]. It has been shown that HIV and malaria infections have a reciprocal effect on each
24 other with a consequent increase in mortality rate [2]. HIV-infected pregnant women have
25 been reported to be at greater risk of placental malaria infection [3]. Ayisi and colleagues
26 has reported that malaria infection during pregnancy may increase the risk of mother-to-child
27 transmission of HIV [4].

28 Trace elements deficiencies and HIV disease however, are thought to interact harmoniously
29 with each other [5]. The authors have shown that micronutrient deficiencies in HIV infected
30 pregnant mothers could lead to disease progression and may contribute to an increased risk
31 of placental malaria and adverse pregnancy outcomes [5]. The implications of these findings
32 in malaria endemic region such as Nigeria form the bases for the present study.

33

34 **2. MATERIAL AND METHODS**

35

36 **2.1 Study Design**

37 This is a case-control study designed to assess the levels of trace elements (Zinc, Selenium,
38 and Magnesium) in naive HIV seropositive subjects with malaria co-infection attending the
39 ante-natal clinic at Nnamdi Azikiwe University Teaching Hospital in Nnewi (NAUTH). One
40 hundred and fifty two (152) consented female participants aged between 18 and 42 years
41 were randomly selected including: HIV seropositive pregnant women with malaria
42 parasitaemia (32), HIV seropositive pregnant women without malaria parasitaemia (30),
43 Malaria infected pregnant women without HIV infection (30), pregnant women without HIV or
44 malaria parasitaemia (30) as control, non-pregnant women without HIV or malaria infection
45 (30) as another controls. All HIV seropositive pregnant women were yet to commence anti-
46 retroviraal therapy (naive). All subjects were screened for HIV seropositivity and malaria
47 parasitaemia. Screening for HIV antibodies was done using Determine and Stat-Pak kit and
48 confirmed with Unigold HIV kit. Pregnancy testing was done using human chorionic
49 gonadotropin (HCG) one step pregnancy test strip. Peripheral malaria was double screened
50 using Rapid Detection Technique (RDT) (2SD) and Giemsa stain thin and thick blood
51 smears microscopy technique.

52 A well-structured questionnaire was administered to each participant to obtain their
53 reproductive history and other biodata. Levels of cytokines were assayed using, Enzyme
54 linked Immunosorbent assay technique, while levels of trace elements zinc, selenium and
55 magnesium were determined using atomic absorption spectrophotometry.

56

57 **2.2 Study site**

58 The study was conducted in Nnamdi Azikiwe University Teaching Hospital (NAUTH) in
59 Nnewi, Anambra State, Nigeria. Laboratory analysis of trace elements was done at
60 Biotechnology Research Center, Nnamdi Azikiwe University, Awka.

61

62 **2.3 Subject recruitment**

63 Purposive sampling technique was employed. The subjects were pregnant women visiting
64 PMCT clinic at NAUTH between December, 2017 and April, 2018 who voluntarily agreed to
65 participate and were subsequently enrolled in the study.

66

67 **2.4 Inclusion and exclusion criteria**

68 Pregnant participants between 18 and 42 years of age with HIV/or malaria infection were
69 included in the study. Non-Pregnant participants seronegative to HIV with or without malaria
70 infection were also included. Pregnant women less than 18 and above 42 years were

71 excluded from the study. Participants who are active smokers, alcoholics, hypertensive and
72 diabetic were excluded. Participant using zinc, selenium and magnesium supplement were
73 also excluded.

74

75 **2.5 Sample collection**

76 Five milliliters (5ml) of venous blood were collected from each of the participants and
77 dispensed 2.5ml each into a well labeled plain container and an EDTA container. The plain
78 bottle sample was allowed to clot and centrifugation was performed at 1500 rpm for 5
79 minutes using bench centrifuge and serum separated for analysis of trace elements.

80

81 **2.6 Laboratory analyses**

82 Determination of HIV-1/2 antibodies was done according to the National algorithm.

83 Malaria parasite screening was done using rapid detection test for *Plasmodium falciparum*
84 malaria antigen as described by Murray and Gresser [6] and Giemsa stained thick and thin
85 blood film for microscopic detection of *P. falciparum* parasites as described by WHO [7].

86 Determination of serum zinc, selenium and magnesium was done using atomic absorption
87 spectrophotometry (AAS) as described by PerkinElmer [8].

88

89 **2.7 Statistical analysis**

90 Statistical package for social sciences (SPSS) version 22 was used for the statistical
91 analysis. The data generated was analyzed using Analysis of variance (ANOVA) to compare
92 more than two independent variables and student's t-test for two independent variables.
93 Pearson correlation was used to correlate different parameters. Values were considered
94 statistically significant if p value $\leq .05$.

95

96 **3. RESULTS AND DISCUSSION**

97

98 **3.1 Values of some anthropometric variables in HIV seropositive pregnant 99 participants with/without malaria co-infection and control participants (mean \pm 100 SD)**

101

102 When the BMI value was compared between the test and control groups, BMI value was
103 significantly lower in HIV seropositive pregnant women with/without malaria co-infection
104 (26.18 ± 2.59 , 26.85 ± 3.10) compared with HIV seronegative pregnant women with/without
105 malaria parasitaemia (28.59 ± 3.70 , 27.21 ± 3.41) ($P = .001$ respectively).

106

107 When the mean DBP was compared between the test and control groups, DBP value was
108 significantly higher in HIV seropositive pregnant women with malaria co-infection (85.53 ± 9
109 $.90$), HIV seronegative pregnant women with malaria parasitaemia (82.96 ± 9.86) compared
110 with HIV seropositive pregnant women without malaria parasitaemia (79.83 ± 9.30) and HIV
111 seronegative pregnant women without malaria parasitaemia (77.60 ± 5.75) ($P \leq .001$
112 respectively). The between group comparison showed that DBP value was significantly
113 higher in HIV seronegative pregnant women with malaria parastaemia (82.96 ± 9.86)
114 compared with HIV seronegative pregnant women without malaria parasitaemia (77.60
115 ± 5.75) ($P = .012$).

116

117 When the mean SBP value was compared between the test and control groups, SBP value
118 was significantly higher in HIV seropositive pregnant women with/without malaria
119 parasitaemia (133.18 ± 8.18 , 125.4 ± 6.71) compared with HIV seronegative pregnant
120 women with/without malaria parasitaemia (127.56 ± 7.14 , 120.43 ± 4.21) ($P = .001$
121 respectively) (Table 1).

122

123

124 **Table 1. Values of some anthropometric parameters in HIV seropositive pregnant**
 125 **women with/without malaria co-infection and control group**

	BMI(kg/m²)	DBP(mmHg)	SBP(mmHg)
	(mean± SD)	(mean ± SD)	(mean ± SD)
HIV seropositive pregnant women with mp (A) n=32	26.18±2.59	85.53±9.90	133.18±8.18
HIV sero-positive pregnant women without mp (B) n=30	26.85±3.10	79.83±9.30	125.4±6.71
HIV seronegative pregnant women with mp (C) n=30	28.59±3.70	82.96±9.86	127.56±7.14
HIV seronegative Pregnant women without mp (Control) (D) n=30	27.21±3.41	73.60±5.75	120.43±4.21
F- Value	7.105	9.68	17.02
P- Value type	0.001	0.001	0.001
A VS B	0.374	0.007	0.001
A VS C	0.002	0.216	0.005
A VS D	0.173	0.001	0.001
B VS C	0.024	0.137	0.277
B VS D	0.638	0.289	0.014

C VS D 0.074 0.012 0.001

126 P was considered statistically significant if $\leq .05$.

127

128 **3.2 Serum zinc, selenium and magnesium levels in HIV seropositive pregnant**
129 **women with/without malaria co-infection and control group**

130

131 When the mean zinc level was compared between the test and control groups, the mean
132 zinc level was significantly lower in HIV seropositive pregnant women with/without malaria
133 co-infection (37.34 ± 6.7 , 36.70 ± 4.39) compared with HIV sero-negative pregnant women
134 with/without malaria parasitaemia (45.1 ± 7.83 , 50.36 ± 8.73) ($P = .001$ respectively).

135

136 The mean level of selenium was compared between the test and control groups, selenium
137 level was significantly lower in HIV seropositive pregnant women with/without malaria co-
138 infection (29.93 ± 6.02 , 28.00 ± 5.04) compared with HIV seronegative pregnant women
139 with/without malaria parasitaemia (31.46 ± 6.19 , 31.96 ± 6.81) ($P = .044$). The between
140 group comparison showed that the mean level of selenium was significantly lower in HIV
141 seropositive pregnant women without malaria parasitaemia (28.00 ± 5.04) compared with
142 HIV seronegative pregnant women with/without malaria parasitaemia (31.46 ± 6.19 , $31.96 \pm$
143 6.81) ($P = .033$, $.015$ respectively).

144

145 When the mean serum magnesium level was compared between the test and control
146 participants, magnesium level was significantly lower in HIV seropositive pregnant women
147 without malaria co-infection (2.33 ± 0.15) and HIV seronegative pregnant women with
148 malaria parasitaemia (2.27 ± 0.14) compared with HIV seronegative pregnant women
149 without malaria infection (2.52 ± 0.30) ($P = .001$). The between group comparison showed
150 that magnesium level was significantly lower in HIV seronegative pregnant women with
151 malaria co-infection (2.27 ± 0.14) compared with HIV seropositive women with malaria
152 parasitaemia (2.33 ± 0.15) ($P = .002$). Also, the mean magnesium level was significantly
153 lower in HIV seronegative pregnant women with malaria parasitaemia (2.27 ± 0.15)
154 compared with HIV seronegative women without malaria parasitaemia (2.52 ± 0.30) ($P =$
155 $.002$) (Table 2).

156

157

158 **Table 2. Serum Levels of zinc, selenium and magnesium in HIV seropositive pregnant**

159 **women with/without malaria co-infection and control groups.**

	Zinc (ug/dl)	Selenium(ng/ml)	Magnesium (mg/dl)
	(mean \pm SD)	(mean \pm SD)	(mean \pm SD)
HIV seropositive pregnant			
women with mp (A)	37.34 ± 6.27	29.93 ± 6.02	2.41 ± 0.16
n=32			

HIV seropositive pregnant women without mp (B) n=30	36.70±4.39	28.00±5.04	2.33±0.15
HIV seronegative pregnant women with mp (C) n=30	45.10±7.83	31.46±6.19	2.27 ±0.14
HIV seronegative Pregnant women without mp. (Control) (D) n=30	50.36±8.73	31.96±6.81	2.52 ± 0.30
F- Value	38.48	2.52	6.61
P- Value type	0.001	0.044	0.001
A VS B	0.747	0.224	0.283
A VS C	0.001	0.336	0.065
A VS D	0.001	0.203	0.186
B VS C	0.001	0.033	0.444
B VS D	0.001	0.015	0.019
C VS D	0.010	0.757	0.002

160 P was considered statistically significant if $\leq .05$.

161

162

163

164 **DISCUSSION**

165

166 Malaria infection seems to accelerate the degree of reduction in micronutrients status during
167 pregnancy. This condition can be worsened by combined effects of HIV infection. In the
168 present study, Zinc level was significantly decreased in HIV seropositive pregnant women
169 with malaria co-infection when compared with control participants. This could be attributed to
170 poor nutritional status and reduction in trace mineral levels among pregnant women. The
171 finding was in agreement with previous reports [9]. Hypozincemia has also been reported in
172 patients with acute illnesses [10]. The reduction in zinc level observed in pregnant women
173 has been implicated in many adverse pregnancy outcomes as a result of malaria infection
174 [9]. Because of the role of zinc in immune modulation [11], it can be deduced that the
175 significant reduction in zinc level in this study, is an indication of response to the challenges
176 of oxidative stress caused by the triple effects of malaria parasites, HIV infection as well as
177 negative effect of pregnancy on the element.

178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230

The significant decrease in zinc level in HIV seronegative pregnant women without malaria parasitaemia compared with the non-pregnant HIV seronegative women without malaria parasitaemia confirmed the increased utilization of zinc in pregnancy for growth of the fetus.

The significant drop in trace element status of HIV seropositive participants with malaria co-infection may be a determinant in ascertaining factors that predisposes or determines severity of the disease in malaria endemic area. Various studies in Nigeria have shown that there is a high prevalence of malaria parasitemia among HIV infected individuals [12]. This means that the impact of the interaction of malaria and HIV will be most apparent in areas with generalized HIV epidemic and malaria endemic areas such as Nigeria. Malaria parasite itself has been reported to contain a complete glutathione redox system especially glutathione reductase, which are very essential to their growth and development showing that inhibition of glutathione reductase in the malaria parasite with improved trace element supplementation represents an important approach to anti-malarial drug development [5].

In this study, selenium level was significantly lower among HIV seropositive pregnant women without malaria parasitaemia, compared with HIV seronegative pregnant women without malaria parasitaemia. This decrease is independent of malaria parasitaemia showing the place of selenium in HIV infection as well as in pregnancy. During pregnancy, a lot of stress is experienced physiologically and pathologically. The physiological stress is due to changes resulting from increased demands for nutrients, and changes in plasma volume. These increased demands eventually lead to decrease in micronutrients. Lower selenium levels may likely increase fetal mortality risk. This is in line with study by (Cosby *et al.* [5] Several authors have linked selenium deficiency in HIV infection to increased oxidative damage, cardiomyopathy and disease progression [13], indicating beneficial effect of antioxidant selenium in inhibition of HIV disease progression and vertical transmission [5,13].

The significant increase in selenium level in parasitemic pregnant women may be due to increased mobilization of this element to fight inflammation caused by parasites' invasion. Furthermore, immune status and selenium concentration are said to increase as parity increases [14]. Increase selenium concentration has also been reported to have some beneficial effects in the treatment of malaria in children [11]; hence we dare to say that increased selenium concentration in parasitemic pregnant women, which may be an inflammatory response, is beneficial to both the pregnant mother and the unborn child.

In this study, the significant decrease observed in mean level of magnesium in HIV seropositive pregnant women with/without malaria co-infection compared with HIV seronegative participants is an indication of magnesium deficiency disease conditions as well as in pregnancy. This increases the demand for adequate supplementation of micronutrient in disease state and pregnancy. Magnesium is essential for many relevant physiological functions, such as bone growth, heart rhythm, vascular tone, nerve function, muscle contraction and relaxation [15]. Variations in the concentration of Mg may be caused by *P. falciparum* malaria, malnutrition as well as malabsorption. There has been a report of increasing demands of adequate magnesium status during pregnancy especially in those from disadvantaged backgrounds [16]. Recent study has also reported decreased adverse pregnant complications with magnesium supplementation [17].

From this study loss of body mass was very significant among HIV seropositive pregnant women with or without malaria co-infection. Consequently, among HIV infected persons, secondary infections or co-infection are also significant predictors of low gestational weight gain [18], possibly through secretion of pro-inflammatory cytokines. Loss of fat mass due to infection during pregnancy might represent a decrease in available substrate for fetal growth. Furthermore, reduction in weight could be a risk factor for chorioamnionitis through

231 impairment in specific immune responses [19], which increases the risk of pregnancy
232 outcomes. The differences in BMI as observed in this study might be that some of the HIV
233 seropositive pregnant women may have been under stress compounded by their poor
234 nutritional and socioeconomic status.

235

236 Significant increase in blood pressure observed in HIV seropositive pregnant women than
237 control pregnant women may indicate possible exposure to hypertension and
238 preeclampsia. This was in line with the previous finding [20]. The authors reported higher
239 prevalence of hypertension in HIV infected than in the HIV uninfected population. The
240 increasing blood pressure could also be related to HIV specific factors such as
241 lipodystrophy, atherogenesis and cytokines activity [21]. Infection with the human
242 immunodeficiency virus type 1 in pregnant women represents an independent risk factor for
243 maternal mortality and adverse pregnancy outcome [22]. Previous report has shown that
244 immune hyperactivity to paternal antigens has been hypothesized to play a role in the
245 development of hypertension in pregnancy, and the immunosuppression caused by HIV
246 could temper the immune response at the placental site and reduce placental
247 vasoconstriction [23]. This potential protection may be a function of the intensity of
248 immunosuppression and may depend on the severity of HIV disease and the use of
249 antiretroviral therapy.

250

251 Notably, just as with the case of HIV seropositive pregnant women without malaria
252 parasitaemia, in this study, there is a significant increase in the diastolic and systolic blood
253 pressure in HIV seronegative pregnant women with malaria parasitaemia when compared
254 with the control. This is in line with an earlier work by Ndao and colleagues [24]. It has been
255 established that in areas of stable endemic malarial transmission such as Nigeria,
256 *Plasmodium falciparum* infection during pregnancy is usually asymptomatic [25]. This is
257 characterized by sequestration of parasites in the placenta. Massive sequestration of
258 parasites in the placenta leads to placental ischemia and other fatal complications [26].
259 However, in normal pregnancy, the earliest stages of development take place in a low
260 oxygen environment- tissue hypoxia [27] and thereby, enhancing the release of reactive
261 oxygen species. This has shown to enhance the release of ROS that are potentially
262 damaging to the cardiovascular system [28]. Pathological stress is mainly due to disease
263 conditions including malaria, HIV and hypertension. The effects of malaria in pregnancy
264 have been well described. It has been documented that malarial infection during pregnancy
265 is a major cause of adverse pregnancy outcomes and maternal complications [22, 25].

266 Oxidative stress has emerged in recent years as a suspected component in the
267 pathogenesis of HIV disease. Research has shown that even in the earliest stages of
268 infection, a deleterious reductive-oxidative (redox) imbalance may occur. Moreover, in
269 response to malaria, HIV, pregnancy and other infections, phagocytic cells such as
270 polymorphonuclear leucocytes and macrophages usually engage in respiratory burst in their
271 attempt to destroy pathogens as a host cell-mediated immune response, with the depleting
272 effect on CD4+T cells, yielding free radicals that react to yield ROS [29]. All these conditions
273 generate enormous oxidative stress especially in pregnancy vis-a-vis HIV/malaria co-
274 infection. This shows that HIV and malaria co-infection causes additional oxidative stress in
275 pregnant women. Since the immune system is constantly stimulated and free radical
276 production is higher than in healthy individuals, adequate intake of antioxidants such as
277 selenium is therefore, critical in minimizing oxidative stress [13, 29]. It has been noted that
278 HIV seropositive pregnant women have a higher risk of developing severe malaria infection
279 particularly in malaria endemic area with attendant immune dysregulation [25, 30]. This can
280 contribute to the sequestering of infected erythrocytes, adhesion of platelets and
281 mononuclear cells [29]. This mechanism of inflammation and sequestration gives rise to
282 tissue stress and significant rise in diastolic and systolic blood pressure as confirmed in this
283 study in HIV seropositive pregnant women with malaria co-infection compared to controls

284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307

4. CONCLUSION

From the findings in this study, HIV and malaria co-infection impact serious significant derangements in micronutrient status (zinc, selenium and magnesium) of HIV seropositive pregnant women with malaria co-infection. There was a significant change in anthropometric parameters (DBP, SBP and BMI) in HIV seropositive pregnant women with malaria co-infection. This could predispose the affected individuals to adverse pregnancy outcomes, pre-eclampsia and hypertension if not adequately managed. It is therefore, strictly recommended that adequate micronutrient supplementations with antioxidant trace minerals be included in routine module for management of HIV seropositive pregnant women with or without malaria co-infection during their antenatal visit especially in regions of malaria endemicity. Further longitudinal study is advocated for clearer picture of micronutrient deficiency in HIV/malaria co-infection in pregnant women.

ACKNOWLEDGEMENTS

Authors wish to acknowledge all the pregnant women who voluntarily gave their written informed consent for success of this study.

308 **COMPETING INTERESTS**

309

310 "Authors have declared that no competing interests exist."

311

312 **AUTHORS' CONTRIBUTIONS**

313

314 "NRU conceptualized and designed the study; 'IUC, ISO, VOA and OBO' managed the
315 literature searches and performed the experiment, 'IUC, VOA, JCA and FAE' analyzed and
316 interpreted the data. 'IUC and NRU' wrote the original manuscript. All authors read and
317 approved the final manuscript".

318

319 **CONSENT**

320

321 "All authors declare that 'written informed consent was obtained from the participants for
322 publication of this research work".

323

324

325 **ETHICAL APPROVAL**

326

327 "All authors hereby declare that all experiments have been examined and approved by the
328 board of human research ethics committee of Nnamdi Azikiwe University Teaching Hospital,
329 Nnewi, Anambra State (NAUTH/CS/66/Vol.10/194/2017/104) and have therefore been
330 performed in accordance with the ethical standards laid down in the 1964 Declaration of
331 Helsinki."

332

333 **REFERENCES**

334

335 1. Kwenti TE, Malaria and HIV coinfection in sub-Saharan Africa: prevalence, impact, and
336 treatment strategies. Res Rep Trop Med 2018; 9: 123–36. doi: [10.2147/RRTM.S154501](https://doi.org/10.2147/RRTM.S154501).

337

338 2. Ezechi O, Petterson KO, Byamugisha J. HIV/AIDS, Tuberculosis, and Malaria in
339 Pregnancy. J Pregnancy 2012; 140826. doi: [10.1155/2012/140826](https://doi.org/10.1155/2012/140826).

340

341 3. Sanyaolu AO, Fagbenro-Beyioku AF, Oyibo WA, Badaru OS, Onyeabor OS, Nnaemeka
342 CI Malaria and HIV co-infection and their effect on haemoglobin levels from three health-
343 care institutions in Lagos, southwest Nigeria. Afr Health Sci 2013; 13:295–300.
344 doi: [10.4314/ahs.v13i2.14](https://doi.org/10.4314/ahs.v13i2.14).

345

346 4. Ayisi JG, van Eijk AM, Newman RD. "Maternal malaria and perinatal HIV transmission,
347 Western Kenya," Emerging Infect Dis 2004; 10:643–652.

348

349 5. Cosby A.S, Kosuke K, Roland K, Wafaie WF. November The Role of Selenium in HIV
350 Infection. Nutri Rev 2010; 68:671–81.

351

352 6. Nandi S, Irlam J, Visser ME, Rollins NN. Micronutrient Supplementation in Pregnant
353 Women with HIV Infection. Review. Cochrane Database Syst Rev 2012; 3: CD009755.
354 DOI: [10.1002/14651858.CD009755](https://doi.org/10.1002/14651858.CD009755).

355

356 7. Murray CK, Gasser RA, Magill AJ, Miller RS. Update on rapid diagnostic testing for
357 malaria. Clin Microbiol Rev 2008; 21:97-110.

358

- 359 8. WHO. Malaria parasite counting. Malaria standard operating procedure. 2016; MMSOP.
360 09.
361
- 362 9. Pathak P, Kapil U, Dwivedi SN, Singh R. Serum zinc levels amongst pregnant women in a
363 rural block of Haryana State, India. *Asian Pac. J Clin Nutr* 2008; 17:276 – 9.
364
- 365 10. Besecker BY, Exline MC, Hollyfield J, Phillips G, Disilvestro RA. A comparison of zinc
366 metabolism, inflammation, and disease severity in critically ill infected and non-infected
367 adults early after intensive care unit admission. *Am J Clin Nutri* 2011; 93:1356–64.
368
- 369 11. Iribhogbe OI, Agbaje EO, Oreagba IA, Aina OO, Ota AD. Therapeutic potential of
370 selected micronutrients in malaria: an in vivo study in *Plasmodium berghei* infected mice.
371 *Biol Med* 2012; 4:193 – 210.
372
- 373 12. Ukibe NR, Onyenekwe CC, Ahaneku JE, Ukibe SN, Meludu SC, Emelumadu OF et al.
374 Evaluation of nutritional status of HIV infected females during menstrual cycle in Nnewi,
375 Anambra state, Nigeria. *Sci J Med Sci* 2013; 2: 169-81. doi: 10.14196/sjms.v2.i9.940.
376
- 377 13. Bella SD, Grilli E, Cataldo MA, Petrosillo N. Selenium Deficiency and HIV Infection.
378 *Infect Dis Rep* 2010; 4; 2: e18. doi: 10.4081/idr.2010.e18.
379
- 380 14. Ogbodo SO, Okaka NC, Nwagha UI. Anti-infective antioxidant minerals levels in
381 uncomplicated pregnancy in some rural communities of South East Nigeria. *J Med Nutraceut*
382 2013; 9:52–7.
383
- 384 15. Jahnen-Dechent W, Ketteler M. Magnesium basics. *Clin kidney J* 2012; 5:13-4.
385
- 386 16. Mohammad YY, Yasir PK, Zulfiqar AB. Maternal mineral and vitamin supplementation in
387 pregnancy. *Expert Rev Obstet Gynecol* 2010; 5 241-56.
388
- 389 17. Elaheh Z and Amal T. Effect of Magnesium Supplement on Pregnancy Outcomes: A
390 Randomized Control Trial. *Adv Biomed Res* 2017; 6:109. doi: 10.4103/2277-9175.213879.
391
- 392 18. Villamor E, Msamanga G, Spiegelman D, Peterson KE, Antelman G, Fawzi WW. Pattern
393 and predictors of weight gain during pregnancy among HIV-1 infected women from Tanzania
394 and HIV-related loss of body mass *J Acquir Immune Def Syndr* 2003; 32:560–9.
395
- 396 19. Galinsky R, Polglase GR, Hooper SB, Black MJ, Moss TJM. The Consequences of
397 Chorioamnionitis: Preterm Birth and Effects on Development. *J Pregnancy* 2013; 412831.
398 doi: 10.1155/2013/412831.
399
- 400 20. Coloma AG, Alvarez AM, Roca-Cusachs CA et al. Prevalence of arterial hypertension
401 and lipid profile in HIV patients. *Medicina Clinica* 2008; 131: 681-4.
402
- 403 21. Sattler FR, Qian D, Louie S. Elevated blood pressure in subjects with therapy on blood
404 pressure in HIV-infected patients. A prospective study in a cohort of naive patients. *AIDS*.
405 2001; 15: 15. DOI: [10.1097/00002030-200110190-00013](https://doi.org/10.1097/00002030-200110190-00013).
406
- 407 22. Ukibe NR, Onyenekwe CC, Anojulu AA, Onwubuya E, Kalu AO, UKIBE SN. Impact of
408 *Plasmodium falciparum* malaria infection on serum cortisol, adrenocorticotrophic hormone,
409 pregnancy associated plasma protein-A and alpha-fetoprotein in pregnant women at Nnewi.
410 *Int J Biol Chem Sci* 2019; 13: 1222-1230, DOI: <https://dx.doi.org/10.4314/ijbcs.v13i3.1>.
411

- 412 23. Malasundera RC, Larbalestier N, Smith JH, de Ruitter A, McG Thom SA, Hughes AD
413 Preeclampsia, antiretroviral therapy, and immune reconstitution. *Lancet* 2002; 360: 1152–4i.
414
- 415 24. Ndao A, Dumont N, Fievet S, Doucoure A, Gaye, Lehesran JY. Placental Malarial
416 Infection as a Risk Factor for Hypertensive Disorders during Pregnancy in Africa: A Case-
417 Control Study in an Urban Area of Senegal. *West Afr Am J Epidemiol* 2009; 170: 847–53.
418
- 419 25. Onyenekwe CC, Meludu SC, Dioka CE, Salimonu LS. Prevalence of Asymptomatic
420 Malaria Parasitaemia amongst Pregnant Women. *Indian J malarial* 2002; 39:60-5.
421
- 422 26. Dorman E, Shulman C. Malaria in pregnancy. Mini-symposium: infections in pregnancy.
423 *Curr trends Obstet Gynecol* 10:183–9.
424
- 425 27. Jauniaux E, Poston L, Burton GJ. Placental-related diseases of pregnancy: involvement
426 of oxidative stress and implications in human evolution. *Hum Repro Update* 2006; 12:747–
427 55.
428
- 429 28. Baillie JK, Bates MG, Thompson AA, Waring WS, Partridge RW, Schnopp MF.
430 Endogenous urate production augments plasma antioxidant capacity in healthy lowland
431 subjects exposed to high altitude. *Chest* 2007; 131:1473 – 8.
432
- 433 29. Clark IA, Budd AC, Alleva LM. Cowden WB. Human malarial disease: a consequence
434 of inflammatory cytokine release. *Malar J* 2006; 5: 85. doi: 10.1186/1475-2875-5-85.
435
- 436 30. French N, Nakiyingi J, Lugada E, Watera C, Whitworth JA., Gilks CF. Increasing rates of
437 malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. *AIDS*
438 2001; 15: 899 – 906.